PALONOSETRON X FOSAPREPITANT IN PONV
关键词
抽象
描述
The prospective, randomized and double-blind clinical trial will be performed at the Federal Hospital of Bonsucesso (HFB), Rio de Janeiro, RJ.
The Informed Consent Form (TCLE) will be presented and signed, on an outpatient basis, by each of the volunteer participants, who will be guided about the risks and benefits of the research, according to resolution CNS 466/12. A total of 100 female patients, aged between 18 and 60 years, ASA I and II, submitted to elective laparoscopic cholecystectomies, were randomly assigned to two groups: Group P (GP) will receive palonosetron 75 mcg and the other Group F GF), you will receive fosaprepitanto 150 mg. Palonosetron and fosaprepitanto are not standard medications in HFB. Both will be purchased and will be in the possession of the principal investigator, who undertakes to obey the current norms of the hospital institution and ensure the quality, storage and adequate stability of medications.
Patients will not receive preanesthetic medication. They will be monitored in the operating room with noninvasive blood pressure, electrocardioscopy, pulse oximetry, capnography, capnometry and bispectral index (BIS).
Patients will have a cannulated peripheral vein, be pre-oxygenated with oxygen at 100% for 5 minutes and anesthetic induction will be performed with intravenous administration (e.v.) of fentanyl 3 mcg / kg; lidocaine 1.5 mg / kg and propofol 2 mg / kg. Tracheal intubation will be facilitated after 3 minutes of administration of rocuronium 0.6 mg / kg e.v. After induction of anesthesia, the antiemetics, depending on the group studied, will be administered e.v. in solution containing 100 ml of 0.9% strength.
Maintenance of anesthesia will be with sevoflurane 2 L / min in 50% oxygen / air, with its concentration adjusted to maintain BIS between 40-60. Remifentanil 0.05 mcg / kg / min at 0.2 mcg / kg / min via e.v. may be given intraoperatively if the heart rate or blood pressure rises by more than 20% of the baseline values. Additional doses of rocuronium may also be given as needed. Patients will receive paracoxib 40 mg, dipyrone 50 mg / kg and ranitidine 50 mg e.v. after tracheal intubation. The surgical wound will be infiltrated with 20 ml of 0.5% ropivacaine before the sutures. The neuromuscular blockade will be reversed with neostigmine 0.04 mg / kg and atropine 0.02 mg / kg per e.v. Morphine 0.03 mg / kg e.v. will be given at the end of the surgery. The inflation of the pneumoperitoneum with CO2 (carbon dioxide), will have as limit abdominal pressure of 15 mmHg.
A physician not participating in the research will be aware of which antiemetic has been administered and will be responsible for the postoperative prescription of the patients. Both groups will have metoclopramide 10 mg e.v. as rescue medication for PONV.
For the purpose of the study, nausea will be defined as an unpleasant and involuntary sensation of vomiting, without the expulsion of stomach contents, and vomiting as expulsion of the stomach contents.
The patients will be visited by the research team 2, 6, 24 and 48 h after the end of the surgery, being questioned about the frequency and intensity of PONV, as well as other adverse effects. Researchers will not have access to prescription and medical records within the first 48 hours postoperatively.
After the last clinical evaluation, the researchers will analyze the prescription and note the use of morphine and rescue metoclopramide. They will also answer a question about the degree of satisfaction with the anti-emetic therapy used and will have 3 "Unsatisfied, satisfied or very satisfied" response options. Regarding the total cost of antiemetic therapy, it will be based on the ANVISA (National Health Surveillance Agency) table.
日期
最后验证: | 02/28/2019 |
首次提交: | 06/28/2018 |
提交的预估入学人数: | 07/12/2018 |
首次发布: | 07/15/2018 |
上次提交的更新: | 03/09/2019 |
最近更新发布: | 03/11/2019 |
实际学习开始日期: | 03/01/2019 |
预计主要完成日期: | 03/01/2019 |
预计完成日期: | 11/30/2020 |
状况或疾病
干预/治疗
Drug: Palonosetrona
Drug: Fosaprepitant
相
手臂组
臂 | 干预/治疗 |
---|---|
Active Comparator: Palonosetrona Palonosetron 75 mcg during the anesthesia | Drug: Palonosetrona 75 mcg during the anesthesia |
Active Comparator: Fosaprepitant Fosaprepitant 150 mg during the anesthesia | Drug: Fosaprepitant 150 mg during the anesthesia |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | Female |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - women - Non fumant - cholelitiasis Exclusion Criteria: - severe heart, pulmonay, renal or liver diseases - Tabagism |
结果
主要结果指标
1. Number of complete responder [48 hours]
次要成果指标
1. Nausea [the first postoperative 48 hours]
2. vomiting [the first postoperative 48 hours]